Clinical Trial Record

Return to Clinical Trials

Does Recurrent Pancreatic Cancer Really Have Similar Outcome Compared With Primary Metastatic Pancreatic Cancer?


2010-01-01


2025-03-01


2025-03-01


276

Study Overview

Does Recurrent Pancreatic Cancer Really Have Similar Outcome Compared With Primary Metastatic Pancreatic Cancer?

The recurrent pancreatic cancer (Rec-PC) after radical surgery is sometimes eligible to clinical trial of chemotherapy for unresectable pancreatic cancer. However, the difference between Rec-PC and primary metastatic pancreatic cancer (PM-PC) did not know well. Thus, whether Rec-PC and PM-PC should be included in the same category when conducting clinical trials evaluating chemotherapy remains controversial. The purpose of this study is to investigate the difference of overall survival (OS) between Rec-PC and PM-PC, and analyze their impact on prognosis.

N/A

  • Pancreatic Cancer Metastatic
  • DRUG: chemotherapy agents
  • Kochi University

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates Results Reporting Dates Study Record Updates

2025-03-13  

N/A  

2025-04-03  

2025-04-03  

N/A  

2025-04-10  

2025-04-10  

N/A  

2025-04  

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

Design Details

Primary Purpose:
N/A


Allocation:
N/A


Interventional Model:
N/A


Masking:
N/A


Arms and Interventions

Participant Group/ArmIntervention/Treatment
: chemotherapy for metastatic pancreatic cancer

chemotherapy

DRUG: chemotherapy agents

  • Overall, data of 276 patients (144 men and 132 women, 224 Rec-PC and 51 PM-PC) were retrospectively analyzed. The median patient age was 70 (range; 29-91) years. Serum carbohydrate antigen (CA) 19-9 among Rec-PC group (median; 207 U/mL) and PM-PC group (m
: chemotherapy for recurrent pancreatic cancer

postoperative chemotherapy

DRUG: chemotherapy agents

  • Overall, data of 276 patients (144 men and 132 women, 224 Rec-PC and 51 PM-PC) were retrospectively analyzed. The median patient age was 70 (range; 29-91) years. Serum carbohydrate antigen (CA) 19-9 among Rec-PC group (median; 207 U/mL) and PM-PC group (m
Primary Outcome MeasuresMeasure DescriptionTime Frame
Overall survivalFrom date of evaluation until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 24 months
Secondary Outcome MeasuresMeasure DescriptionTime Frame

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person’s general health condition or prior treatments.

Ages Eligible for Study:
ALL

Sexes Eligible for Study:

Accepts Healthy Volunteers:

    Inclusion Criteria:

  • unresectable pancreatic cancer

  • Exclusion Criteria:

  • Patients expected to survive for less than three months

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Publications

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

No publications available